Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1994 Apr;96(1):8–14. doi: 10.1111/j.1365-2249.1994.tb06221.x

B7/BB1 provides an important costimulatory signal for CD3-mediated T lymphocyte proliferation in patients with systemic lupus erythematosus (SLE).

P P Sfikakis 1, R Oglesby 1, P Sfikakis 1, G C Tsokos 1
PMCID: PMC1534533  PMID: 7512010

Abstract

Successful T cell activation via the T cell receptor (TCR)/CD3 complex requires at least one contact-dependent second signal delivered by costimulatory molecules, including the B7/BB1 molecule, that are present on antigen-presenting cells (APC). SLE is characterized by multiple complex lymphocyte abnormalities of undefined molecular origin. It is currently unclear whether an intrinsic defect of T cell or an underlying APC dysfunction is responsible for defective in vitro proliferation of T cells from patients with SLE. We planned the present experiments to ask whether the TCR/CD3-mediated and B7/BB1-costimulated T cell proliferation is normal in these patients. We used enriched T cell populations that were stimulated with an anti-CD3 MoAb in the presence of controlled quantities of functional B7/BB1 antigen. Freshly isolated T cells from 17 SLE patients (10 and seven patients with either active or inactive disease, respectively) and 11 normal individuals were cocultured with irradiated B7/BB1-transfected P815 cells or parental P815 cells in the presence of OKT3 MoAb at optimal and suboptimal concentrations for 2.5-7 days. Normal or SLE T cells responded similarly to stimulation via anti-CD3, in the absence of B7/BB1 antigen. A several-fold increase in T cell proliferation in the presence of B7/BB1 antigen was observed. Proliferation was inhibited in the presence of anti-B7/BB1 MoAb, but not with control MoAbs. Interestingly, dose-response curves and time kinetics of B7/BB1 costimulation were similar in T cells from patients with either active or inactive SLE at the time of study, and normal individuals. In addition, no differences in the IL-2 receptor release by T cells cultured under these conditions were observed between SLE patients and normal individuals. These results demonstrate that CD28 signalling is not intrinsically impaired in patients with SLE; further studies to investigate whether abnormal B7/BB1 expression is involved in the autoimmune process are needed.

Full text

PDF
8

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alcocer-Varela J., Alarcón-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest. 1982 Jun;69(6):1388–1392. doi: 10.1172/JCI110579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Altman A., Coggeshall K. M., Mustelin T. Molecular events mediating T cell activation. Adv Immunol. 1990;48:227–360. doi: 10.1016/s0065-2776(08)60756-7. [DOI] [PubMed] [Google Scholar]
  3. Altman A., Theofilopoulos A. N., Weiner R., Katz D. H., Dixon F. J. Analysis of T cell function in autoimmune murine strains. Defects in production and responsiveness to interleukin 2. J Exp Med. 1981 Sep 1;154(3):791–808. doi: 10.1084/jem.154.3.791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Angel J., Colard O., Chevy F., Fournier C. Interleukin-1-mediated phospholipid breakdown and arachidonic acid release in human synovial cells. Arthritis Rheum. 1993 Feb;36(2):158–167. doi: 10.1002/art.1780360205. [DOI] [PubMed] [Google Scholar]
  5. Azuma M., Cayabyab M., Buck D., Phillips J. H., Lanier L. L. CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. J Exp Med. 1992 Feb 1;175(2):353–360. doi: 10.1084/jem.175.2.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Azuma M., Yssel H., Phillips J. H., Spits H., Lanier L. L. Functional expression of B7/BB1 on activated T lymphocytes. J Exp Med. 1993 Mar 1;177(3):845–850. doi: 10.1084/jem.177.3.845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Clevers H., Alarcon B., Wileman T., Terhorst C. The T cell receptor/CD3 complex: a dynamic protein ensemble. Annu Rev Immunol. 1988;6:629–662. doi: 10.1146/annurev.iy.06.040188.003213. [DOI] [PubMed] [Google Scholar]
  8. Damle N. K., Linsley P. S., Ledbetter J. A. Direct helper T cell-induced B cell differentiation involves interaction between T cell antigen CD28 and B cell activation antigen B7. Eur J Immunol. 1991 May;21(5):1277–1282. doi: 10.1002/eji.1830210527. [DOI] [PubMed] [Google Scholar]
  9. Fox D. A., Millard J. A., Treisman J., Zeldes W., Bergman A., Depper J., Dunne R., McCune W. J. Defective CD2 pathway T cell activation in systemic lupus erythematosus. Arthritis Rheum. 1991 May;34(5):561–571. doi: 10.1002/art.1780340508. [DOI] [PubMed] [Google Scholar]
  10. Freedman A. S., Freeman G. J., Rhynhart K., Nadler L. M. Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol. 1991 Oct 15;137(2):429–437. doi: 10.1016/0008-8749(91)90091-o. [DOI] [PubMed] [Google Scholar]
  11. Freedman A. S., Freeman G., Horowitz J. C., Daley J., Nadler L. M. B7, a B-cell-restricted antigen that identifies preactivated B cells. J Immunol. 1987 Nov 15;139(10):3260–3267. [PubMed] [Google Scholar]
  12. Freeman G. J., Lombard D. B., Gimmi C. D., Brod S. A., Lee K., Laning J. C., Hafler D. A., Dorf M. E., Gray G. S., Reiser H. CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production. J Immunol. 1992 Dec 15;149(12):3795–3801. [PubMed] [Google Scholar]
  13. Gimmi C. D., Freeman G. J., Gribben J. G., Sugita K., Freedman A. S., Morimoto C., Nadler L. M. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6575–6579. doi: 10.1073/pnas.88.15.6575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gutierrez-Ramos J. C., Andreu J. L., Revilla Y., Viñuela E., Martinez C. Recovery from autoimmunity of MRL/lpr mice after infection with an interleukin-2/vaccinia recombinant virus. Nature. 1990 Jul 19;346(6281):271–274. doi: 10.1038/346271a0. [DOI] [PubMed] [Google Scholar]
  15. Harding F. A., McArthur J. G., Gross J. A., Raulet D. H., Allison J. P. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature. 1992 Apr 16;356(6370):607–609. doi: 10.1038/356607a0. [DOI] [PubMed] [Google Scholar]
  16. Hishikawa T., Tokano Y., Sekigawa I., Ando S., Takasaki Y., Hashimoto H., Hirose S., Okumura K., Abe M., Shirai T. HLA-DP+ T cells and deficient interleukin-2 production in patients with systemic lupus erythematosus. Clin Immunol Immunopathol. 1990 May;55(2):285–296. doi: 10.1016/0090-1229(90)90104-x. [DOI] [PubMed] [Google Scholar]
  17. Huang Y. P., Miescher P. A., Zubler R. H. The interleukin 2 secretion defect in vitro in systemic lupus erythematosus is reversible in rested cultured T cells. J Immunol. 1986 Dec 1;137(11):3515–3520. [PubMed] [Google Scholar]
  18. Huang Y. P., Perrin L. H., Miescher P. A., Zubler R. H. Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus. J Immunol. 1988 Aug 1;141(3):827–833. [PubMed] [Google Scholar]
  19. Kaneoka H., Morito F., Yamaguchi M. Low responsiveness to the anti Leu 4 antibody by T cells from patients with active systemic lupus erythematosus. J Clin Lab Immunol. 1989 Jan;28(1):15–26. [PubMed] [Google Scholar]
  20. Katz J. D., Senecal J. L., Rivest C., Goulet J. R., Rothfield N. A simple severity of disease index for systemic lupus erythematosus. Lupus. 1993 Apr;2(2):119–123. doi: 10.1177/096120339300200210. [DOI] [PubMed] [Google Scholar]
  21. Kawasaki K., Yaoita E., Yamamoto T., Tamatani T., Miyasaka M., Kihara I. Antibodies against intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 prevent glomerular injury in rat experimental crescentic glomerulonephritis. J Immunol. 1993 Feb 1;150(3):1074–1083. [PubMed] [Google Scholar]
  22. Kroemer G., Wick G. The role of interleukin 2 in autoimmunity. Immunol Today. 1989 Jul;10(7):246–251. doi: 10.1016/0167-5699(89)90262-4. [DOI] [PubMed] [Google Scholar]
  23. Linker-Israeli M., Bakke A. C., Kitridou R. C., Gendler S., Gillis S., Horwitz D. A. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol. 1983 Jun;130(6):2651–2655. [PubMed] [Google Scholar]
  24. Linsley P. S., Brady W., Grosmaire L., Aruffo A., Damle N. K., Ledbetter J. A. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med. 1991 Mar 1;173(3):721–730. doi: 10.1084/jem.173.3.721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Martorell J., Font J., Rojo I., Vilella R., Ingelmo M., Vives J. Responsiveness of systemic lupus erythematosus T cells to signals provided through LCA T200 (CD45) and T1 (CD5) antigens. Clin Exp Immunol. 1989 Nov;78(2):172–176. [PMC free article] [PubMed] [Google Scholar]
  26. Miyasaka N., Nakamura T., Russell I. J., Talal N. Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol. 1984 Apr;31(1):109–117. doi: 10.1016/0090-1229(84)90195-8. [DOI] [PubMed] [Google Scholar]
  27. Murakawa Y., Sakane T. Deficient phytohemagglutinin-induced interleukin-2 activity in patients with inactive systemic lupus erythematosus is correctable by the addition of phorbol myristate acetate. Arthritis Rheum. 1988 Jul;31(7):826–833. doi: 10.1002/art.1780310702. [DOI] [PubMed] [Google Scholar]
  28. Norton S. D., Zuckerman L., Urdahl K. B., Shefner R., Miller J., Jenkins M. K. The CD28 ligand, B7, enhances IL-2 production by providing a costimulatory signal to T cells. J Immunol. 1992 Sep 1;149(5):1556–1561. [PubMed] [Google Scholar]
  29. Rubin L. A., Kurman C. C., Fritz M. E., Biddison W. E., Boutin B., Yarchoan R., Nelson D. L. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol. 1985 Nov;135(5):3172–3177. [PubMed] [Google Scholar]
  30. Rubin L. A., Nelson D. L. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med. 1990 Oct 15;113(8):619–627. doi: 10.7326/0003-4819-113-8-619. [DOI] [PubMed] [Google Scholar]
  31. Santoro T. J., Luger T. A., Ravache E. S., Smolen J. S., Oppenheim J. J., Steinberg A. D. In vitro correction of the interleukin 2 defect of autoimmune mice. Eur J Immunol. 1983 Jul;13(7):601–604. doi: 10.1002/eji.1830130717. [DOI] [PubMed] [Google Scholar]
  32. Scholz W., Isakov N., Mally M. I., Theofilopoulos A. N., Altman A. Lpr T cell hyporesponsiveness to mitogens linked to deficient receptor-stimulated phosphoinositide hydrolysis. J Biol Chem. 1988 Mar 15;263(8):3626–3631. [PubMed] [Google Scholar]
  33. Schwartz R. H. A cell culture model for T lymphocyte clonal anergy. Science. 1990 Jun 15;248(4961):1349–1356. doi: 10.1126/science.2113314. [DOI] [PubMed] [Google Scholar]
  34. Schwartz R. H. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell. 1992 Dec 24;71(7):1065–1068. doi: 10.1016/s0092-8674(05)80055-8. [DOI] [PubMed] [Google Scholar]
  35. Stekman I. L., Blasini A. M., Leon-Ponte M., Baroja M. L., Abadi I., Rodriguez M. A. Enhanced CD3-mediated T lymphocyte proliferation in patients with systemic lupus erythematosus. Arthritis Rheum. 1991 Apr;34(4):459–467. doi: 10.1002/art.1780340411. [DOI] [PubMed] [Google Scholar]
  36. Stohl W. Impaired generation of polyclonal T cell-mediated cytolytic activity despite normal polyclonal T cell proliferation in systemic lupus erythematosus. Clin Immunol Immunopathol. 1992 May;63(2):163–172. doi: 10.1016/0090-1229(92)90009-d. [DOI] [PubMed] [Google Scholar]
  37. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  38. Tan P., Anasetti C., Hansen J. A., Melrose J., Brunvand M., Bradshaw J., Ledbetter J. A., Linsley P. S. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med. 1993 Jan 1;177(1):165–173. doi: 10.1084/jem.177.1.165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Thiele D. L., Kurosaka M., Lipsky P. E. Phenotype of the accessory cell necessary for mitogen-stimulated T and B cell responses in human peripheral blood: delineation by its sensitivity to the lysosomotropic agent, L-leucine methyl ester. J Immunol. 1983 Nov;131(5):2282–2290. [PubMed] [Google Scholar]
  40. Tsokos G. C. Pathogenesis of human systemic lupus erythematosus. Introduction. Clin Immunol Immunopathol. 1992 Apr;63(1):3–3. doi: 10.1016/0090-1229(92)90081-x. [DOI] [PubMed] [Google Scholar]
  41. Urowitz M. B., Gladman D. D., Tozman E. C., Goldsmith C. H. The lupus activity criteria count (LACC). J Rheumatol. 1984 Dec;11(6):783–787. [PubMed] [Google Scholar]
  42. Vandenberghe P., Freeman G. J., Nadler L. M., Fletcher M. C., Kamoun M., Turka L. A., Ledbetter J. A., Thompson C. B., June C. H. Antibody and B7/BB1-mediated ligation of the CD28 receptor induces tyrosine phosphorylation in human T cells. J Exp Med. 1992 Apr 1;175(4):951–960. doi: 10.1084/jem.175.4.951. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Weaver C. T., Unanue E. R. The costimulatory function of antigen-presenting cells. Immunol Today. 1990 Feb;11(2):49–55. doi: 10.1016/0167-5699(90)90018-5. [DOI] [PubMed] [Google Scholar]
  44. Wolf R. E., Brelsford W. G. Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum. 1988 Jun;31(6):729–735. doi: 10.1002/art.1780310605. [DOI] [PubMed] [Google Scholar]
  45. Wuthrich R. P., Yui M. A., Mazoujian G., Nabavi N., Glimcher L. H., Kelley V. E. Enhanced MHC class II expression in renal proximal tubules precedes loss of renal function in MRL/lpr mice with lupus nephritis. Am J Pathol. 1989 Jan;134(1):45–51. [PMC free article] [PubMed] [Google Scholar]
  46. Yokochi T., Holly R. D., Clark E. A. B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas. J Immunol. 1982 Feb;128(2):823–827. [PubMed] [Google Scholar]
  47. Young J. W., Koulova L., Soergel S. A., Clark E. A., Steinman R. M., Dupont B. The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro. J Clin Invest. 1992 Jul;90(1):229–237. doi: 10.1172/JCI115840. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES